Home | Welcome to Contract Pharma   
Last Updated Wednesday, August 20 2014
Print

Evotec Earns Roche Milestone in Biomarker Pact



Published April 24, 2014
Related Searches: Development Validation Phase I
Evotec AG has achieved a milestone in its biomarker alliance with Roche. Roche will use a response prediction marker, identified using Evotec's Proteome Profiling platform, in an extended Phase I oncology trial.
 
This is the first milestone achieved under the collaboration and license agreement signed in 2011. Under the initial three-year term, Evotec and Roche conduct biomarker discovery and validation programs for patient stratification in targeted cancer therapy. Evotec is eligible for further success-based payments upon clinical companion diagnostics development.
 
Dr. Mario Polywka, chief operating officer of Evotec AG, said, "We are delighted with receiving this milestone and the first validation of our novel biomarker concept with Roche. I would like to thank everyone involved in the project to date for the fantastic science they have developed and for the hard work and determination to see it succeed in a clinical setting."


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On